PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Diabetes & Metabolism Journal10.4093/dmj.2022.01312022464663-664Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)Tomoyuki Kawadahttp://e-dmj.org/upload/pdf/dmj-2022-0131.pdf, http://e-dmj.org/journal/view.php?doi=10.4093/dmj.2022.0131, http://e-dmj.org/upload/pdf/dmj-2022-0131.pdf
Diabetes & Metabolism Journal10.4093/dmj.2022.01662022464665-666Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)Hwi Seung Kim, Woo Je Leehttp://e-dmj.org/upload/pdf/dmj-2022-0166.pdf, http://e-dmj.org/journal/view.php?doi=10.4093/dmj.2022.0166, http://e-dmj.org/upload/pdf/dmj-2022-0166.pdf
Diabetes & Metabolism Journal10.4093/dmj.2021.02322022464658-662Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World StudyHwi Seung Kim, Taekwan Yoon, Chang Hee Jung, Joong-Yeol Park, Woo Je Leehttp://e-dmj.org/upload/pdf/dmj-2021-0232.pdf, http://e-dmj.org/journal/view.php?doi=10.4093/dmj.2021.0232, http://e-dmj.org/upload/pdf/dmj-2021-0232.pdf
Canadian Journal of Diabetes10.1016/j.jcjd.2020.09.0052021453291-302Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 DiabetesRonald M. Goldenberg, Vineeta Ahooja, Kristin K. Clemens, Jeremy D. Gilbert, Megha Poddar, Subodh Vermahttps://api.elsevier.com/content/article/PII:S1499267120303671?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1499267120303671?httpAccept=text/plain
Diabetes10.2337/db22-1477-pub202271Supplement_11477-PUB: The Comparison between Sodium–Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide 1 Receptor Agonist Treatment Depending on the Change in Blood Pressure in Japanese Patients with Type 2 Diabetes Mellitus on the Renal FunctionKAZUO KOBAYASHI, MASAO TOYODA, NOBUO HATORI, KOUICHI TAMURAhttps://diabetesjournals.org/diabetes/article/71/Supplement_1/1477-PUB/146587/1477-PUB-The-Comparison-between-Sodium-Glucose, https://diabetesjournals.org/diabetes/article/71/Supplement_1/1477-PUB/146587/1477-PUB-The-Comparison-between-Sodium-Glucose
Journal of Diabetes Investigation10.1111/jdi.1306620191061518-1526Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical studyYasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, Hideki Suganami, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kakuhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/jdi.13066, https://onlinelibrary.wiley.com/doi/full-xml/10.1111/jdi.13066, https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdi.13066
Frontiers in Endocrinology10.3389/fendo.2020.00553202011Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-AnalysisYoon Ji Kim, Seun Deuk Hwang, Soo Limhttps://www.frontiersin.org/article/10.3389/fendo.2020.00553/full
European Heart Journal Supplements10.1093/eurheartj/suaa129202022Supplement_LL28-L32The new type 2 diabetes mellitus therapy: comparison between the two classes of drugs GLPR (glucagon-like peptide receptor) agonists and SGLT2 (sodium–glucose cotransporter 2) inhibitorsClaudio Borghi, Alessio Bragagnihttp://academic.oup.com/eurheartjsupp/article-pdf/22/Supplement_L/L28/34386900/suaa129.pdf, http://academic.oup.com/eurheartjsupp/article-pdf/22/Supplement_L/L28/34386900/suaa129.pdf
Diabetes Research and Clinical Practice10.1016/j.diabres.2021.1090352021180109035Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world settingFederico Rea, Stefano Ciardullo, Laura Savaré, Gianluca Perseghin, Giovanni Corraohttps://api.elsevier.com/content/article/PII:S0168822721003946?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168822721003946?httpAccept=text/plain
Canadian Journal of Diabetes10.1016/j.jcjd.2018.09.0012019433186-192Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence StudyJuana Carretero Gómez, José Carlos Arévalo Lorido, Ricardo Gómez Huelgas, Dolores García de Lucas, Lourdes Mateos Polo, José Manuel Varela Aguilar, Jose Miguel Seguí Ripoll, Javier Enahttps://api.elsevier.com/content/article/PII:S1499267118303423?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1499267118303423?httpAccept=text/plain